Nivolumab plus ipilimumab achieves higher response rates than previously reported for nivolumab alone.

中文翻译：

---

Nivolumab和Ipilimumab在dMMR / MSI-H肿瘤中获得应答

尼伏鲁单抗加依普利单抗的应答率比以前报道的尼伏鲁单抗高。